Bolt Biotherapeutics
BOLT
62 hedge funds and large institutions have $165M invested in Bolt Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 20 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
0.27% less ownership
Funds ownership: 4.77% → 4.51% (-0.27%)
13% less funds holding
Funds holding: 71 → 62 (-9)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
63% less capital invested
Capital invested by funds: $449M → $165M (-$284M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.69M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$8.59M |
| 3 |
Morgan Stanley
New York
|
+$2.55M |
| 4 |
BlackRock
New York
|
+$1.84M |
| 5 |
Holocene Advisors
New York
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$20.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.5M |
| 3 |
SC
Samlyn Capital
New York
|
-$9.38M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$3.25M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$2.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
76
Point72 Hong Kong
Hong Kong
| – | -$26K | -105 | Closed |
|
77
UBS Group
Zurich,
Switzerland
| – | -$2.28K | -12 | -92% |
|
78
US Bancorp
Minneapolis,
Minnesota
| – | -$3K | -12 | Closed |
|
|
S
79
SignatureFD
Atlanta,
Georgia
| – | -$949 | -5 | -63% |
|
|
PA
80
Parallel Advisors
San Francisco,
California
| – | -$1K | -4 | Closed |
|
|
TC
81
TAP Consulting
Kirkwood,
Missouri
| – | +$190 | +1 | New |
|
|
EI
82
Ellevest Inc
New York
| – | +$569 | +3 | New |
|
BOLT Hedge Fund Activity: Q4 2021 in Review
62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2021, worth a combined $165M — down 63% from $449M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of BOLT and 11 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 25 added.
The largest buyer was Eventide Asset Management, adding an estimated $8.69M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $20.9M sold.
- 62 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2021, down from 71 in Q3 2021.
- Funds reported $165M of Bolt Biotherapeutics stock for Q4 2021, down 63% quarter-over-quarter.
- 11 funds opened new Bolt Biotherapeutics positions in Q4 2021 and 20 closed out, a net change of -9 holders.
- The largest Bolt Biotherapeutics buyer in Q4 2021 was Eventide Asset Management, an estimated $8.69M added.
- The largest Bolt Biotherapeutics seller in Q4 2021 was Rock Springs Capital Management, an estimated $20.9M sold.
Based on aggregated 13F filings for Q4 2021.